UBS Says Nike Stock Has No Good Entry Point as Revenue Outlook Worsens

Since Nike reported better-than-expected Q4 results, the company's forward guidance has become the focus, and it isn't good.

The Guidance Got Worse

On Tuesday evening, Nike management told investors that revenue declines over the next two quarters will be steeper than previously forecast. The company now expects sales to fall in the low-to-mid single digits, a step down from an earlier projection of a low-single-digit decline, according to ZeroHedge's reporting on the earnings call.

Outgoing CFO Matt Friend was direct: "We are not expecting the environment to improve meaningfully over the next six months." He added that customers are "under pressure around the world, and we can particularly see it having a larger impact on sportswear."

The primary culprit cited by management is slower wholesale shipments in North America. The operating environment, according to Nike, became "increasingly challenging" as the fourth quarter progressed, with North America showing a measurable slowdown by mid-April.

Shares Down in Premarket

Nike shares fell roughly 3% in premarket trading following the earnings call, reflecting investor reaction to the guidance revision rather than the headline Q4 numbers, which were largely in line with expectations.

The stock has been in a multi-year decline and is now trading at levels last seen in approximately 2014, according to ZeroHedge.

UBS: Not Cheap Enough to Bottom-Fish

UBS equity analyst Jay Sole, who covers retail, department stores, specialty softlines, apparel, footwear, and consumer discretionary stocks, sent a blunt message to clients: "We don't see a reason to buy the stock."

Sole's concern isn't just about the near-term sales miss. It's about valuation. Even after the extended selloff, Nike is trading at roughly 27 times UBS's fiscal 2027 EPS estimate — a multiple that, in Sole's view, still prices in a meaningful recovery that the company has NOT yet demonstrated it can deliver.

"The pivotal Nike question remains: 'Is all the bad news now priced in?'" Sole wrote. His answer: not yet.

Sole did acknowledge the main upside scenario — Nike returns to positive sales growth with expanding gross margins faster than expected. That would justify a higher multiple and reward patient buyers. But he sees that outcome as balanced against significant downside risk, with no catalyst visible in the near term to break the tie.

The Fairest Case for Staying Patient

There is a reasonable bull argument worth taking seriously. Nike is still one of the most globally recognized consumer brands on the planet. Management has signaled a deliberate reset focused on product innovation and pulling back from discounting. Turnarounds of this kind — repositioning a brand that got bloated and over-distributed — genuinely do take multiple years. Critics of the bearish view would argue that the current stock price already reflects the worst-case scenario and that investors selling now are locking in losses ahead of a recovery.

Sole's response to that argument is the valuation itself. At 27 times forward earnings, the stock is NOT pricing in the worst case. It's pricing in an eventual recovery. If that recovery takes longer than the market expects — or doesn't happen at the pace embedded in consensus estimates — the stock has further room to fall.

CFO Transition and What Lies Ahead

The timing adds an institutional wrinkle. Matt Friend is the outgoing CFO, with a transition to incoming CFO David Denton pending. How quickly Denton establishes credibility with investors — and whether Nike's reset shows any measurable traction under his tenure — is among the most consequential open questions the company faces heading into fiscal 2027.

UBS's Sole hasn't set a revised price target in the excerpt available, but his framing — balanced upside and downside with no identifiable entry point — effectively tells institutional clients to stay on the sideline until the revenue trend actually turns, not until management says it will.